Skip to content
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Evolving Psychedelic Paradigm
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
JCP Podcast
Rounds in the General Hospital
View All
John Panagides, PhD
JCP
Original Research
A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment
February 22, 2011
John M. Kane
,
Armin Szegedi
,
Mary Mackle
, et al
JCP
Original Research
Efficacy and Tolerability of Asenapine in Acute Schizophrenia: A Placebo- and Risperidone-Controlled Trial
October 15, 2007
Steven G. Potkin
,
John Panagides
,
Miriam Cohen
JCP
Original Research
Efficacy of Mirtazapine for Prevention of Depressive Relapse: A Placebo-Controlled Double-Blind Trial of Recently Remitted High-Risk Patients
October 1, 2001
Andrew A. Nierenberg
,
Michael E. Thase
,
Martin B. Keller
, et al
JCP
Article
Development of New Antidepressants
May 1, 1997
Stephen M. Stahl
,
John Panagides
,
Angelo Sambunaris
, et al
